Home › Ovarian Cancer › Oklahoma
Ovarian Cancer clinical trials in Oklahoma
31 studies for Ovarian Cancer are looking for participants at sites in Oklahoma.
Cities in Oklahoma
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
All ages · All sexes · Updated Sep 29, 2026 · NCT05564377Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- OU Health, Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT05739981FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Clinical Pre-screening Protocol for Ovarian Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RecruitingObservational study
Ages 18 and older · Women · Updated Jul 30, 2026 · NCT03877796A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
- Oklahoma Cancer Specialists and Research Institute, Tulsa
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 14, 2026 · NCT04606914A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Jun 2, 2026 · NCT07024784Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingHealthy volunteers welcome
Ages 50 to 74 · Women · Updated May 6, 2026 · NCT00539162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 14, 2026 · NCT06234423A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05932862From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.